top of page

#KNOWVEMBER 
IS PRECISION ONCOLOGY AWARENESS MONTH

this month is about understanding the science that’s already changing the future of cancer care and the work we do all year to make it accessible to everyone.

LIBRARY & SYSTEM UPDATES

what is happening in precision oncology across canada

Find the developments shaping precision oncology in Canada, brought together from across the field. See what’s changing, explore the evidence and go straight to the source.

SYSTEM UPDATES

recent changes

april 2026

Canada’s Drug Agency published its Biomarker Assessment Framework for Cancer Care, a structured approach for provinces deciding which biomarker tests to assess and fund. provinces still make their own funding decisions.

Canada’s Drug Agency

december 2025

results from a pan-canadian liquid biopsy program for advanced solid tumours were published in Current Oncology. the study was designed and led by a test manufacturer.

Current Oncology

july 2026

Ontario Health’s Comprehensive Cancer Biomarker Testing Program list of funded tests and testing sites was updated, effective july 1, 2026. new additions include CLDN 18.2 for gastric cancer, a pancreatic cancer panel and mismatch repair testing for any progressed solid tumour.

Ontario Health (Cancer Care Ontario)

june 2026

Québec launched its first genomic medicine policy, with initial funding that includes $1.2 million for companion diagnostics and $200,000 for genomic profiling in oncology. an action plan with Santé Québec will follow.

Gouvernement du Québec

june 2026

INESSS recommended public coverage of liquid biopsy (ctDNA) profiling for people with advanced, progressing breast cancer in Québec, with conditions including a dedicated test code and yearly monitoring. tissue testing remains the standard.

INESSS

june 2026

Québec launched its first genomic medicine policy, with initial funding that includes $1.2 million for companion diagnostics and $200,000 for genomic profiling in oncology. an action plan with Santé Québec will follow.

Gouvernement du Québec

november 2026

researchers at CHU Sainte-Justine showed that a single whole-genome test can profile a child's cancer in about 72 hours instead of two to four weeks. it is already used for newly diagnosed children at four Québec pediatric centres.

Université de Montréal

october 2026

INESSS opened an evaluation of the IDH1 R132 test used to decide who can receive ivosidenib (Tibsovo). comments are open until november 12, 2026.

INESSS

september 2024

New Brunswick introduced liquid biopsy for lung cancer patients, with samples collected at regional facilities across the province. funding came from the province and AstraZeneca.

CBC News

september 2026

Health Canada committed $80 million over four years, matched for a total of $160 million, to phase 2 of the Terry Fox Research Institute's Marathon of Hope Cancer Centres Network. the announcement does not say whether Québec centres are included.

Health Canada

september 2026

a Lancet Oncology Commission estimates that four in five people with cancer who need standard molecular testing don't get it, and sets out tools for health systems to check their readiness, workforce and progress.

The Lancet Oncology

aug-sep 2025

Canada’s Drug Agency consulted on a draft framework for assessing cancer biomarker tests and set up a dedicated team to assess companion diagnostics.

Canada’s Drug Agency

jan–feb 2026

Canada’s Drug Agency consulted on changes to drug reimbursement reviews, including assessing a broader range of tests linked to precision therapies (complementary as well as companion tests). consultation closed february 26.

Canada’s Drug Agency

july 2026

a five-year trial led by University Health Network will offer liquid biopsies to more than 7,000 patients after curative treatment, to study whether ctDNA can signal recurrence.

CBC News

june 2026

INESSS recommended public coverage of liquid biopsy (ctDNA) profiling for people with advanced, progressing breast cancer in Québec, with conditions including a dedicated test code and yearly monitoring. tissue testing remains the standard.

INESSS

june 2026

the updated State of Readiness report finds canada only partially ready for genomic medicine. Alberta and Newfoundland and Labrador are best prepared; Ontario made the most progress since 2023; only Québec has an established funding formula for new tests. the study was industry-funded.

Husereau et al., Current Oncology

march 2025

an environmental scan was conducted to identify and synthesize existing information related to frameworks and processes that currently inform the assessment, implementation, and funding decisions for genetic and genomic biomarker testing as well as what biomarker testing is currently available or being funded in cancer care across Canada.

Canada's Drug Agency

november 2026

researchers at CHU Sainte-Justine showed that a single whole-genome test can profile a child's cancer in about 72 hours instead of two to four weeks. it is already used for newly diagnosed children at four Québec pediatric centres.

Université de Montréal

october 2026

INESSS opened an evaluation of the IDH1 R132 test used to decide who can receive ivosidenib (Tibsovo). comments are open until november 12, 2026.

INESSS

september 2026

a Lancet Oncology Commission estimates that four in five people with cancer who need standard molecular testing don't get it, and sets out tools for health systems to check their readiness, workforce and progress.

The Lancet Oncology

september 2026

Health Canada committed $80 million over four years, matched for a total of $160 million, to phase 2 of the Terry Fox Research Institute's Marathon of Hope Cancer Centres Network. the announcement does not say whether Québec centres are included.

Health Canada

who’s doing what, and which tests are funded where.

THE LANDSCAPE

reports, research and guidance

THE LIBRARY

from researchers, agencies, governments, clinicians and colab.

Biomarqueurs tumoraux liés à la prise en charge des personnes atteintes d'une tumeur solide (tumour biomarkers for solid tumours)
INESSS · updated august 2026 · français
providers, decision makers

for

Environmental Scan of Genetic and Genomic Biomarker Testing Assessment Frameworks, Processes, and Inventories in Cancer Care
Canada’s Drug Agency · Canadian Journal of Health Technologies · 2025
decision makers, industry

for

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Metastatic Breast Cancer 2025
Jerzak et al. · Breast Cancer Canada · Current Oncology · 2026
providers, advocates

for

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2026)
ESMO
providers

for

CCC Skin Cancer Pathway Map
cancer care ontario
providers

for

ESMO Recommendations on clinical reporting of genomics test results for solid cancers (Nov 2024)
ESMO
providers, decision makers

for

Assessment Framework for Biomarkers Used in Cancer Care
Canada’s Drug Agency · april 2026
decision makers, industry, providers

for

Ontario Genetic Test Directory
Ontario Health
providers

for

Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada
conference report · Current Oncology · 2024
providers, decision makers

for

A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology Tests
peer-reviewed study
providers, advocates

for

Draft framework for assessing cancer biomarker tests (consultation)
Canada’s Drug Agency · 2025
decision makers, industry

for

Genetic testing resources for health care providers
Ontario Health (Cancer Care Ontario)
providers

for

Profilage moléculaire de l'ADN tumoral circulant à partir d'une biopsie liquide : cancer du sein (ctDNA profiling for breast cancer)
INESSS · june 2026 · français
decision makers, providers

for

Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission
Casolino et al. · The Lancet Oncology · 2026
decision makers, advocates

for

Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma
Brezden-Masley et al. · Current Oncology · 2024
providers

for

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2026)
ESMO
providers

for

CCC Breast Cancer Pathway Map
cancer care ontario
providers

for

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group (Feb 2025)
ESMO
providers

for

Plasma Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: recommendation
Ontario Health · november 2024
decision makers, providers

for

Progress toward Health System Readiness for Genome Based Testing in Canada
Husereau et al. · Current Oncology · 2023
decision makers, industry

for

Implementation of Liquid Biopsy in Non Small Cell Lung Cancer: An Ontario Perspective
Breadner et al. · Current Oncology · 2024
providers, decision makers

for

Comprehensive Cancer Biomarker Testing Program: funded tests and testing sites
Ontario Health (Cancer Care Ontario) · as of july 1, 2026
providers, advocates

for

Proposed enhancements to drug reimbursement reviews, including testing procedure assessments
Canada’s Drug Agency · 2026
industry, decision makers

for

ASCO 2026: testing dependent therapies and what Canada needs in place
the cancer collaborative · 2026
decision-makers, industry

for

Politique québécoise en médecine génomique (Québec genomic medicine policy)
Gouvernement du Québec · june 2026 · français
decision makers, industry, advocates

for

Precision medicine: a pathway to targeted, personalized and equitable care (World Health Assembly resolution)
World Health Organization · may 2026
decision makers

for

Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper
Schaeffer et al. · CCTG Pathology Working Group · Current Oncology · 2026
providers, decision makers

for

CCC pathway maps
cancer care ontario
providers

for

CCC Lung Cancer Pathway Map
cancer care ontario
providers

for

Readiness to Consider and Adopt Genetic and Genomic Tests in Canada: An Update to the State of Readiness Report
Husereau et al. · Current Oncology · 2026
decision makers, industry

for

Provincial Laboratory Formulary
Government of Newfoundland and Labrador
providers, industry

for

Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada
conference report · Current Oncology · 2025
providers, decision makers

for

Exploring Cancer Patients’ and Caregivers’ Perspectives and Knowledge Regarding Biomarker Testing in Canada
Current Oncology · 2025
advocates, providers

for

Biopsies liquides : avis (liquid biopsy recommendation)
INESSS · august 2024 · français
decision makers, providers

for

Environmental scan: pharmaceuticals requiring companion diagnostics
CADTH (now Canada’s Drug Agency)
industry, decision makers

for

  • threads
  • LinkedIn
  • Spotify
  • Youtube
  • bluesky
  • Apple Music
  • Threads
bottom of page